Applies to the following strength(s): 12.5 mg ; 25 mg ; 6.25 mg
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Diabetes Type 2
Usual dose: 25 mg orally once a day
Comments: When used in combination with insulin or insulin secretagogues such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be required to minimize the risk of hypoglycemia.
Use: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; may be used as monotherapy or in combination therapy .
Renal Dose Adjustments
Mild Renal Impairment (CrCl 60 mL/min or greater): No adjustment recommended
Moderate Renal Impairment (CrCl 30 to 60 mL/min): 12.5 mg orally once a day
Severe Renal Impairment (CrCl 15 mL to less than 30 mL/min): 6.25 mg orally once a day
ESRD (CrCl less than 15 mL/min): 6.25 mg orally once a day
Liver Dose Adjustments
Mild to moderate liver dysfunction (Child-Pugh Grade A and B): No adjustment recommended
Severe liver dysfunction (Child-Pugh C): Data not available. Use caution
-If liver injury is detected, promptly interrupt therapy and assess for probable cause.
-If liver injury is confirmed and no alternative etiology is found, do not restart this drug.
If used in combination with insulin or an insulin secretagogue such as sulfonylureas, a lower dose of insulin or the insulin secretagogue may be required to minimize the risk of hypoglycemia.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Hemodialysis: 6.25 mg orally once a day; may be administered without regard to the timing of dialysis
Peritoneal dialysis: Data not available
-Take orally once a day
-May take with or without food
If a dose is missed take as soon as remembered; but if it is time for your next dose, skip the missed dose
-May be used as monotherapy or in combination therapy in adults with type 2 diabetes mellitus.
-Not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis as it would not be effective in these settings.
-Renal: Assess renal function at baseline and periodically during therapy
-Hepatic for signs and symptoms of hepatotoxicity
-Monitor for signs and symptoms of pancreatitis
-Monitor glycemic control
-Instruct patient to report signs and symptoms of pancreatitis; if persistent, severe abdominal pain occurs, seek medical advice promptly.
-Hypoglycemia may occur, more commonly when used in combination with insulin or a sulfonylurea.
-Patients should understand the importance of adhering to dietary instructions and regular physical activity; during periods of stress such as fever, trauma, infection, or surgery, management of diabetes may change and patients should be advised to seek medical advice.
-Instruct patients to contact their health care provider if they develop severe and persistent joint pain.
More about alogliptin
- Other brands: Nesina